# Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

> **NCT04655261** · — · TERMINATED · sponsor: **AbbVie** · enrollment: 5 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04655261
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-12
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of Recruitment
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655261, "Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04655261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*